Breast cancer immunotherapy: Realities and advances.

Cancer Innov

Jacinto Convit World Organization Inc. Pompano Beach Florida USA.

Published: October 2024

AI Article Synopsis

  • Breast cancer is the most prevalent malignant tumor and leading cause of female mortality globally.
  • Advances in immunology and understanding tumor escape mechanisms have led to the development of various promising immunotherapy strategies, including monoclonal antibodies and anticancer vaccines.
  • Despite progress, challenges like treatment resistance and low response rates still exist, necessitating careful evaluation of ongoing clinical trials and approved therapies.

Article Abstract

Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide. With increased knowledge regarding tumor escape mechanisms and advances in immunology, many new antitumor strategies such as nonspecific immunotherapies, monoclonal antibodies, anticancer vaccines, and oncolytic viruses, among others, make immunotherapy a promising approach for the treatment of BC. However, these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers. In this article, we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416644PMC
http://dx.doi.org/10.1002/cai2.140DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
cancer immunotherapy
4
immunotherapy realities
4
realities advances
4
advances breast
4
cancer common
4
common malignant
4
malignant tumor
4
tumor main
4
main death
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!